You are here: Industry Insights > cancer

News List

Lupin announces achievement of key milestones for its clinical stage MEK inhibitor compound expresspharma
May 31, 2021
Lupin’s MEK inhibitor compound is planned for clinical development in combination with Boehringer Ingelheim’s KRAS inhibitor pipeline to address KRAS-driven cancers.
Beroni, tella Sign MoU for Cancer Immunotherapy Treatment contractpharma
May 31, 2021
Beroni Group, an Australia-based biopharmaceutical enterprise, has signed a Memorandum of Understanding with tella, Inc. to collaborate in the field of immunotherapy for cancer treatment.
NHS England funds first national metastatic breast cancer audit pharmatimes
May 25, 2021
NHS England (NHSE) has announced that it will fund the first ever national metastatic breast cancer audit, in a bid to provide accurate figures of how many people in England are living with secondary breast cancer.
As Medicaid Access Expands, So Does Cancer Survival drugs
May 20, 2021
More lower-income Americans are surviving cancer due to expanded Medicaid health care coverage, a new study shows.
Farrer Park Hospital Elevates Cancer Care with PIPAC Treatment for Late to End-stage Cancer Patients prnasia
May 19, 2021
Farrer Park Hospital has introduced the pressurized intraperitoneal aerosolized chemotherapy (PIPAC) treatment for patients with peritoneal cancer, offering this vulnerable group a second chance to achieve better quality of life.
DarwinHealth Announces a Research Collaboration with Bristol Myers Squibb for a Novel Cancer Target Discovery (NCTI) Initiative prnasia
May 07, 2021
DarwinHealth, a New York City-based biotechnology company, announced a scientific research collaboration with Bristol-Myers Squibb Company.
Varian and Icon Group Partner to Extend Commitment to Global Cancer Care prnasia
April 28, 2021
Varian, a Siemens Healthineers company, has signed an agreement with Australia's Icon Group to provide 30 linear accelerators and associated treatment software to help tackle the growing global cancer burden.
MSIG partners with Singapore Cancer Society to raise public awareness on cancer risks prnasia
April 27, 2021
MSIG Insurance and Singapore Cancer Society today announced a 3-year collaboration to advance public awareness on cancer risks.
PARP inhibitors could exploit weaknesses in a range of cancers pharmatimes
April 26, 2021
PARP inhibitors – a type of drug most commonly used to treat ovarian and breast cancers – could offer a new way of targeting a range of cancers with a particular gene defect in the PBRM1 gene, according to researchers.
LINDIS Biotech Reports Successful Initiation of Clinical Phase I Dose Escalation Study with the Trifunctional Antibody CATUMAXOMAB for Treatment of Non-Muscle-Invasive Bladder Cancer americanpharmaceuticalreview
April 14, 2021
LINDIS Biotech GmbH, a biopharmaceutical company with a proprietary multi-specific antibody platform and an advanced development pipeline with three clinical product candidates in immuno-oncology, announced the successful initiation of its clinical ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 87 88 Next page